Global Tacrolimus Market 2026–2035 expanding with transplant medicine demand

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Tacrolimus Market Evolve From 2026 To 2030?

The tacrolimus market size has seen substantial growth in recent years. It is projected to expand from $6.97 billion in 2025 to $7.39 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.0%. This historical growth can be linked to the rise in organ transplantation procedures, the proven clinical efficacy of tacrolimus, an increasing prevalence of autoimmune and inflammatory conditions, enhanced transplant success rates, and the expansion of healthcare infrastructure for transplant care.

The tacrolimus market size is anticipated to undergo significant expansion over the next few years, projected to reach $9.06 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.2%. This growth during the forecast period is primarily driven by an increasing number of kidney and liver transplants, the escalating demand for cost-effective generic drugs, expanded off-label use in dermatology, advancements in immunosuppressive drug monitoring, and the proliferation of transplant programs in emerging economies. Noteworthy trends for the forecast period include a rising demand for post-transplant immunosuppressive therapies, broader application of tacrolimus in dermatological uses, a growing inclination towards generic immunosuppressant drugs, improved long-term organ transplant survival rates, and greater adoption of topical tacrolimus formulations.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15679&type=smp

What Drivers Are Influencing The Tacrolimus Market?

The tacrolimus market is anticipated to expand due to a rising number of organ transplant procedures. Organ transplantation involves surgically replacing a non-functional organ by transferring an organ or tissue from a donor to a recipient. The demand for these transplantations is increasing, driven by advancements in medical technology, improved surgical techniques, greater public awareness of organ donation, and superior post-transplant care. Tacrolimus plays a crucial role in organ transplantation by suppressing T-cell activation and decreasing cytokine production, which prevents the immune system from rejecting the new organ. For example, the Organ Procurement and Transplantation Network, a US-based non-profit organization, reported in January 2025 a slight increase in kidney transplants, reaching 27,759 in 2024, marking a 1.6 percent rise from 2023. Conversely, heart transplant procedures stayed largely consistent, with 4,572 performed in 2024 compared to 4,545 in 2023. Consequently, the growing volume of organ transplant procedures is fueling the tacrolimus market. The expanding geriatric population is projected to stimulate the growth of the tacrolimus market. The geriatric population consists of individuals generally 65 years and older, who are older adults facing distinct healthcare, social, and physiological demands linked with aging. This demographic rise is mainly attributed to increased life expectancy, enabling more individuals to live longer due to improved healthcare, better management of diseases, and enhanced living standards. Tacrolimus assists the geriatric population by regulating immune responses to avert organ rejection and handle autoimmune diseases, thereby addressing the heightened vulnerability to immune-related issues in older individuals. For example, data from July 2024, provided by the UK Parliament’s House of Commons Library, a UK-based government administration, showed 12.7 million people aged 65 or above in the UK in 2022, constituting 19% of the overall population. This figure is forecast to grow to 22.1 million by 2072, making up 27% of the population. Thus, the escalating geriatric population is propelling the expansion of the tacrolimus market.

Which Segment Areas Are Covered In The Tacrolimus Market Analysis?

The tacrolimus market covered in this report is segmented –

1) By Product Type: Tacrolimus Capsules And Tablets, Tacrolimus Injection, Tacrolimus Granules

2) By Application: Immunosuppression, Other Applications

3) By End User: Organ Transplant Centers, Hospitals, Clinics, Other End Users

Subsegments:

1) By Tacrolimus Capsules And Tablets: Oral Capsules, Oral Tablets

2) By Tacrolimus Injection: Injectable Solution, Injectable Powder

3) By Tacrolimus Granules: Oral Granules (For Suspension)

What Key Developments And Trends Are Impacting The Tacrolimus Market?

Leading companies in the tacrolimus market are actively engaged in developing advanced pharmaceuticals, such as tacrolimus ointments, to cater to the increasing demand for innovative treatments for dermatological conditions while simultaneously enhancing patient care. Tacrolimus ointment functions as a topical treatment that contains tacrolimus, an immunosuppressive agent primarily utilized for managing inflammatory skin conditions. For example, in August 2023, Glenmark, an India-based pharmaceutical company, received approval from the United States Food and Drug Administration (US FDA) for Tacrolimus Ointment 0.03%, which is the generic equivalent of Protopic Ointment 0.03%. Glenmark Pharmaceuticals will be responsible for distributing Tacrolimus Ointment, 0.03%, throughout the United States. This drug is prescribed for treating moderate-to-severe atopic dermatitis, a skin ailment characterized by inflammation, redness, and itching.

Which Global Companies Are Actively Competing In The Tacrolimus Market?

Major companies operating in the tacrolimus market are Astellas Pharma Inc, Novartis AG, Abbott Laboratories, Viatris Inc., Teva Pharmaceutical Industries Limited, Sandoz Inc, Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Lupin Limited, Hikma Pharmaceuticals, Biocon Ltd., Zydus Lifesciences Limited, Torrent Pharmaceuticals Limited, Alembic Pharmaceuticals Limited, Wockhardt Limited, Zhejiang Hisun Pharmaceutical Co. Ltd., Huadong Medicine Co Ltd, Glenmark Pharmaceuticals Ltd., Panacea Biotec

Read the full tacrolimus market report here:

https://www.thebusinessresearchcompany.com/report/tacrolimus-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Tacrolimus Market?

North America was the largest region in the tacrolimus market in 2025. The regions covered in the tacrolimus market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Tacrolimus Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15679&type=smp

Browse Through More Reports Similar to the Global Tacrolimus Market 2026, By The Business Research Company

Tacrolimus Market Report 2026

https://www.thebusinessresearchcompany.com/report/tacrolimus-global-market-report

Hard Seltzer Market Report 2026

https://www.thebusinessresearchcompany.com/report/hard-seltzer-global-market-report

Saccharin Market Report 2026

https://www.thebusinessresearchcompany.com/report/saccharin-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795